These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 31639630)

  • 1. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
    Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
    Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
    Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
    J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
    Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
    Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adult IDH wild-type lower-grade gliomas should be further stratified.
    Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
    Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.
    Aliotta E; Nourzadeh H; Batchala PP; Schiff D; Lopes MB; Druzgal JT; Mukherjee S; Patel SH
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1458-1463. PubMed ID: 31413006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.